Daniel J. Nevrivy, Ph.D.
Dr. Nevrivy is an intellectual property (IP) attorney and he counsels clients on domestic and international IP procurement and enforcement. He has extensive experience helping clients maximize the value of their IP and represents individuals, startups, emerging firms, leading research universities, and global corporations. He has expertise in the life sciences and pharmaceutical sciences and has successfully assisted clients for nearly 20 years in these fields. He has drafted and prosecuted hundreds of domestic and international patent applications that span the entire breadth of the life sciences, including therapeutic antibodies and biologics, vaccines, diagnostics, therapeutic compositions and methods, drug formulation and delivery technologies, gene therapies, cell therapies, stem cells and regenerative medicine, genome editing, cancer immunotherapies, and therapeutic devices.
Dr. Nevrivy’s practice further includes counseling preclinical and clinical stage development companies regarding intellectual property strategies and portfolio management. He advises clients regarding freedom to operate, due diligence, patentability, invalidity and noninfringement. In particular, he has significant experience helping companies navigate the complex patent issues associated with the development and launch of proprietary products.
Dr. Nevrivy also maintains an active pro bono practice representing disabled U.S. veterans in their IP matters who are graduates of the Entrepreneurship Boot Camp (EBV) program run by Syracuse University.
He conducted scientific research in the fields of molecular and cellular biology and molecular pharmacology and has authored several research articles in the fields of cancer, cell biology and transcriptional activation and repression.
Some of his recent speaking engagements, honors, and publications include:
Strategies for Obtaining Biotech and Pharmaceutical Patents in the United States, Guangzhou, China (October 2019)
Cross-border Camp Talk: Strategic considerations for obtaining patents on your intellectual property assets, China Focus@Europe, Vienna, Austria (March 2019)
Recent Developments in Patent Eligibility, Divided Infringement, and Protection of Antibodies – Chinese Biopharmaceutical Association, USA, Intellectual Property Protection in Biopharmaceutical Industry (October 2018)
Moderated panel discussion entitled How to Grow your Startup IP practice at the 33rd Annual Intellectual Property Law Conference – American Bar Association (April 2018)
“The BPCIA Patent Dance – What Biosimilar Companies Need To Know,” The Knowledge Group Webcast, January 2017
Life Sciences Patent Attorney of the Year – Mid-Atlantic USA (Acquisition International 2017 Legal Awards)
US (DC) – Patent attorney of the year, ACQ Global Awards 2016
“Lawyers Offer Predictions for Myriad, Diagnostic Field Based on Supreme Court’s Decision Against Prometheus “ Genetic Engineering & Biotechnology News
“Intellectual Property – Some Business Considerations,” Symposium on Entrepreneurship – A Tool Kit for Launching a University Based Start-Up, University of Maryland BioPark.
“Life Science Patent Eligibility in the Midst of Myriad, Classen and Prometheus,” In-House Counsel Continuing Legal Education
Academic & Pharma Partnerships: Tapping the Ivory Tower for the Next Blockbuster, FiercePharma
“Caveats in Patent Overhaul Could Pose New Challenges for Smaller Biopharmas” Genetic Engineering & Biotechnology News
“Implementation of European Court Decision to Ban hESC Patents Depends on National Patent Offices” Genetic Engineering & Biotechnology News
“Asia’s Emerging Markets Catching Up to the U.S. and Europe in Terms of Innovation” Genetic Engineering & Biotechnology News
“The Myriad Genetics Ruling – was the global biotech industry gutted? “National Public Radio (Tech Nation), to listen click here.
“Alkermes To Put Its Long-Acting Stamp On Trusted Blockbusters, Starting With Abilify,” “The Pink Sheet,” Elsevier, February 2010
“Saving Roman” – a video about the childhood cancer neuroblastoma produced by the Biotechnology Industry Organization (BIO) and showcased at the 2009 BIO International Convention keynote luncheon